{
  "docId": "019de073-8079-71bb-b12b-cbebf2163a3a",
  "docSlug": "9b4d00e952721e20753466aee3e72db7",
  "documentTitle": "BenevolentAI | Investor Day Presentation Deck | 74 slides",
  "authorId": "benevolentai",
  "authorName": "BenevolentAI",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 74,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 20,
  "notes": "The chart uses a horizontal bar format to compare IND filing rates against market capitalization for different tiers of pharma companies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-8079-71bb-b12b-cbebf2163a3a/18",
  "deckHref": "/decks/019de073-8079-71bb-b12b-cbebf2163a3a",
  "deckJsonHref": "/decks/019de073-8079-71bb-b12b-cbebf2163a3a.json",
  "deckAnchorHref": "/decks/019de073-8079-71bb-b12b-cbebf2163a3a#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.75,
        "y": 0.3
      },
      "kind": "callout",
      "text": "BenevolentAI potential productivity is in line with medium and large companies, but at a fraction of the total cost.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca33ba9b-b888-4095-b2a3-954aa23875b7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.45,
        "x": 0.2,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Number of new INDs filed by year by pharma and biotech companies",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9e67f4c-6015-46f4-8dc2-61958796379e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.75,
        "y": 0.5
      },
      "kind": "paragraph",
      "text": "BenevolentAI will aim to increase the number of INDs from its Platform with incremental cost largely from development through to the clinic only",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "89fa3f98-7896-4ed0-a9b6-744d0dcf0b04",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Note *IND filing rate is based on Phase I trial starts with the company as the lead sponsor. Average adjusted for companies which started clinical development during time period; 1 Market cap as of 06 September 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fe642345-85b0-46d0-ad27-668623ca2628",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "What that equates to: higher productivity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d91685a-2df5-4329-a54f-5dc4a43416b4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "5d00165b-d5e6-469f-a6aa-3af7994ffedb",
      "evidence": "BenevolentAI will aim to increase the number of INDs from its Platform with incremental cost largely from development through to the clinic only",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "8ddcbe6c-1331-48e0-be27-4089278ee38a",
      "evidence": "Comparing IND filing rates across peer groups to establish relative productivity.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 74,
      "from": 8,
      "beatId": "e075ee7a-56af-49ed-87dd-38efd7ca183a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The Benevolent Platform™: a versatile, scalable and proven AI-enabled R&D engine",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 22,
      "from": 8,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "e2251468-93de-4ace-9654-ae81abca33ea",
      "evidence": "The Benevolent Platform™: a versatile, scalable and proven AI-enabled R&D engine",
      "position": 1,
      "objective": "Explain the benefits of the Benevolent Platform™",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.8,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}